-+ 0.00%
-+ 0.00%
-+ 0.00%

Q32 Bio reports 36-week Phase 2a SIGNAL-AA data showing 35.3% mean SALT score reduction for bempikibart in alopecia areata

PUBT·09/30/2026 13:15:30
Listen to the news
Q32 Bio reports 36-week Phase 2a SIGNAL-AA data showing 35.3% mean SALT score reduction for bempikibart in alopecia areata
  • Q32 Bio disclosed additional Week 36 results from Part B of its Phase 2a SIGNAL-AA trial of bempikibart in severe alopecia areata.
  • Results were presented at EADV Congress 2026 in late-breaking oral and poster sessions; topline data had been released in July 2026.
  • The study showed clinically meaningful hair regrowth, with responses seen across patient subgroups, supporting a move toward registrational development.
  • Follow-up off treatment indicated durable control, with many patients maintaining or improving hair regrowth, supporting less frequent maintenance dosing concepts.
  • Safety was generally well tolerated with no new safety signals, bolstering plans to start a registration-directed program in H1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609300915PR_NEWS_USPR_____NE59955) on September 30, 2026, and is solely responsible for the information contained therein.